Wednesday, October 25, 2017 10:40:45 AM
https://smithonstocks.com/antares-approval-of-xyosted-is-a-matter-of-when-not-if-atrs-2-12-buy/
It's a subscription site, so I don't want to cut&paste the whole article. One main point is that the pharmacokinetic parameters are within other products on the market ... it's actually better than other products from the FDA noted perspective.
(Again, see http://www.smsna.org/scottsdale2016/presentations/131.pdf)
Still hmmm on this one from the FDA.
VPR Brands LP Reports Record Annual Financial Performance for Fiscal Year 2023 • VPRB • Apr 19, 2024 11:24 AM
Coinllectibles' Subsidiary, Grand Town Development Limited, Acquires Rare Song Dynasty Ceramics Worth Over USD28million • COSG • Apr 18, 2024 8:03 AM
ILUS Provides Form 10-K Filing Update • ILUS • Apr 17, 2024 9:54 AM
Glucotrack Announces Expansion of Its Continuous Glucose Monitoring Technology to Epidural Glucose Monitoring • GCTK • Apr 17, 2024 8:00 AM
Maybacks Global Entertainment To Fire Up 24 New Stations in Louisiana • AHRO • Apr 16, 2024 1:30 PM
Cannabix Technologies Begins Certification of Contactless Alcohol Breathalyzer, Re-Brands product series to Breath Logix • BLOZF • Apr 16, 2024 8:52 AM